Drug Profile
AGEN 2373
Alternative Names: AGEN-2373Latest Information Update: 12 Jun 2023
Price :
$50
*
At a glance
- Originator Agenus
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant melanoma; Solid tumours
Most Recent Events
- 05 Jun 2023 Interim adverse events and efficacy data from a phase I trial in Solid tumours released by Agenus
- 05 Jun 2023 Agenus plans clinical trials in Cancer (Monotherapy, Combination therapy) (IV)
- 02 Jun 2023 Efficacy, safety and pharmacokinetics data from phase I trial in Solid tumours presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)